低氧诱导因子在疾病治疗中的新进展——2019年诺贝尔生理学或医学奖成果简析

New progress of hypoxia inducible factor in the treatment of diseases

低氧诱导因子是一种异二聚体结构的DNA结合转录因子,它可以与特定的核辅因子结合,激活多种基因,在缺氧条件下优化氧的利用。美国癌症学家William G.Kaelin Jr、英国医学家Sir Peter J.Ratcliffe和美国医学家Gregg L.Semenza因发现了细胞如何感知和适应氧可用性,获得了2019年的诺贝尔生理学或医学奖,其中HIF发挥了重要的作用。介绍了HIF在肾性贫血、肿瘤、心血管疾病等治疗中的研究进展,探讨了其对人类健康的意义。

The hypoxia inducible factor(HIF)is a heterodimer DNA-binding transcription factor that can bind with specific nuclear cofactors and activate a variety of genes to optimize the oxygen utilization under hypoxia conditions.The American oncologist William G.Kaelin Jr.,the British medical scientist Sir Peter J.Ratcliffe and the American medical scientist Gregg L.Semenza won the 2019 Nobel Prize in Physiology or Medicine for discovering how cells sense and adapt to the oxygen availability where the HIF plays an important role.This paper reviews the research progress of the HIF in the treatment of renal anemia,tumor,cardiovascular disease,as well as its significance to human health.